Vascular endothelial growth factor (VEGFA) gene variation in polycystic ovary syndrome in a Tunisian women population

Assila Ben Salem¹*, Fatma Megdich¹, Olfa Kacem³, Malek Souayeh¹, Faten Hachani Ben Ali², Sondes Hizem¹, Faouzi Janhai¹, Mounir Ajina³, Muhammad Abu-Elmagd⁴, Mourad Assidi³, Mohammed H. Al Qahtani³ and Touhami Mahjoub¹

From 3rd International Genomic Medicine Conference
Jeddah, Saudi Arabia. 30 November - 3 December 2015

Abstract

Background: Polycystic ovary syndrome (PCOS) is characterized by the growth of a number of small cysts on the ovaries which leads to sex hormonal imbalance. Women who are affected by this syndrome suffer from irregular menstrual cycles, decline in their fertility, excessive hair growth, obesity, acne and most importantly cardiac function problems. The vascular endothelial growth factor (VEGF) plays a pivotal role in tissue vascularization in general and in the pathogenesis of many diseases. The PCOS was found to be associated with high expression levels of VEGF. In women who undergo assisted reproductive procedures (ART), VEGF was found to be a key mediator of other factors to control ovary angiogenesis. Here, we set out to examine the association of VEGFA gene polymorphism with PCOS and its components in a population of Tunisia women to enhance our understanding of the genetic background leading angiogenesis and vascularization abnormalities in PCOS.

Methods: The association of VEGFA gene with PCOS and its components was examined in a cohort of 268 women from Tunisia involving 118 PCOS patients and 150 controls. VEGFA gene variations were assessed through the analysis of the following SNPs rs699947 (A/C), rs833061 (C/T), rs1570360 (G/A), rs833068 (G/A), rs3025020 (C/T), and rs3025039 (C/T). The linkage disequilibrium between SNPs was assessed using HAPLOVIEW software while combination of SNPs into haplotypes in the population and the reconstruction of the cladogram were carried-out by PHASE and ARLEQUIN programs, respectively. Genetic association and genotype-phenotype correlations were calculated by logistic regression and non-parametric tests (Kruskall-Wallis and Mann–Whitney tests), respectively, using StatView program.

Results: We observed 10 haplotypes in our studied cohort where H1 (ACGG), H2 (ACAG), H7 (CTGG) and H8 (CTGA) were the most frequent. We observed the association of the genotype CT of the SNP rs30225039 with PCOS phenotype (P = 0.03; OR 95% CI = 2.05 [1.07–3.90]) and a trend for correlation of the pair of haplotypes H2/H2 with prolactin levels in plasma (P = 0.077; 193.5 ± 94.3 vs 45.7 ± 7.2). These data are consistent with literature and highlight one more time the role of vascularization in the pathogeny of PCOS.

(Continued on next page)
Background

The polycystic ovary syndrome (PCOS) is a disease affecting 6 – 12 % of women at reproductive age and characterized by abnormalities in relation to reproduction, hyperandrogenism as well as metabolic abnormalities like insulin resistance, obesity, impaired fasting glucose (IGF) and metabolic syndrome (MetS) [1, 2].

Knowing the role of blood flow and vascular pattern of an organ in the organ’s morphology and function, previous studies focused on the comparison of blood flow and vascularization between women with PCOS and healthy women showing larger and more vascularized ovaries in PCOS women compared to the control [3]. Moreover, abnormalities in ovarian angiogenesis were involved in the ovarian hyperstimulation syndrome (OHSS) and other disorders of anovulation, subfertility and pathogenic conditions as endometriosis [4]. In this context, the vascular endothelial growth factor (VEGF) system, composed of ligands and receptors plays a pivotal role in tissue vascularization and endothelial cell growth [5]. It was also reported to induce cell proliferation, promote cell migration, inhibit apoptosis and induce permeabilization of blood vessels. It is a major component of the family of angiogenic factors, which includes placental growth factor, angiopoetin, basic fibroblast growth factor and the VEGF family (A, B, C, D and E). VEGFA in particular is a protein encoded by a gene (Gene ID: 7422) located in chromosome 6 and extended on more than 16 kb (GRCh37/hg19; chr6: 43737946–43754224). The gene involves 8 exons and encodes for many VEGFA isoforms as VEGF-165 and VEGF-145.

Previous studies reported the association of VEGFA gene with PCOS through SNPs +9812, +13553, −2578 (rs699947), −460 (rs833061) and +405 [6, 7] and their haplotypes in populations of different origins [6–8]. Moreover, SNPs +405 and −460 were reported as having a trend towards higher insulin resistance [9]. It was suggested the role of some of these SNPs on the regulation of VEGFA gene expression and protein production and secretion [10].

In this context, we focused on the study of the association of VEGFA gene with PCOS and its components in a population of women from Tunisia well characterized at the phenotypic level. The aim was to better characterize the genetic background responsible for angiogenesis and vascularization abnormalities in PCOS. This will be achieved through testing the association of VEGFA gene in a population where it was previously highlighted the need for haplotyping approach in order to understand better the genetic association in populations with mosaic anthropogenetic components [11, 12].

Subjects and methods

1. Subjects

Following an informed consent, a total of 268 unrelated Tunisian women, consisting of 118 PCOS patients and 150 controls. PCOS patients group (mean age: 29.8 ± 0.4 years) were recruited from the outpatient Obstetrics and Gynecology Department, CHU Farhat Hached (Sousse) in Central Tunisia (Table 2). The diagnosis of PCOS was based on the 2003 Rotterdam Criteria [13]. PCOS was then attested when two of the following three conditions are observed: anovulation, hyperandrogenism, and the presence of polycystic ovaries on ultrasound examination. Exclusion criteria were androgen-producing tumors, 21-hydroxylase-deficiency, non-classical adrenal hyperplasia, hyperprolactinemia, active thyroid disease, and Cushing’s syndrome. Control group consisted of 150 healthy women (mean age: 33.5 ± 0.5 years), with regular menstrual cycles and no evidence of hirsutism, acne, alopecia, or endocrinopathies. None of the controls was on hormonal therapy (including oral contraceptives) for the previous three months or longer, and none of PCOS women or controls was on medication known to affect carbohydrate metabolism or endocrine parameters, at least for the last three months before inclusion in the study. Demographic data and history of hypertension, diabetes, and hypercholesterolemia were recorded for all subjects. Obesity was defined as body-mass index (BMI) ≥30 kg/m². The protocol of the study was approved by the local ethics committee, and written informed consent was obtained from all subjects.

2. SNPs genotyping

Total genomic DNA was isolated from peripheral blood lymphocytes by the salting-out method. Six SNPs were selected because of their association with PCOS, angiogenesis and other metabolic components in literature: rs699947 (A/C), rs833061 (C/T),
rs1570360 (G/A), rs833068 (G/A), rs3025020 (C/T), and rs3025039 (C/T). The 6 SNPs were genotyped by the allelic discrimination TaqMan SNP Genotyping Assays (Applied Biosystems; Foster City, CA). The PCR primers and TaqMan probes were directly available from Applied Biosystem (predesigned assays) and analyses were done according to the manufacturer’s protocol on a StepOne plus apparatus (Applied Biosystems) (Table 1).

Statistical analysis
Data were expressed as mean ± SE (continuous variables) or as percent of total (categorical variables), and intergroup significance was assessed by \( \chi^2 \) test. Allele frequencies were calculated by gene-counting method; each SNP was tested for Hardy–Weinberg equilibrium using Haploview 4.2 (http://www.broadinstitute.org/haploview). Linkage disequilibrium (LD) was assessed using Haploview 4.2. Genetic association and genotype-phenotype correlation were assessed by logistic regression and non-parametric tests (Mann–Whitney and Kruskall-Walli tests) using StatView program.

Calculation of the power of the study was assessed using SAMPSIZE software (http://sampsize.sourceforge.net).

Results and discussions
Phenotype data
Women with PCOS have higher BMI than controls \((P < 0.0001; 28.4 \pm 0.7 \text{ vs } 23.1 \pm 0.2 \text{ kg/m}^2)\), higher random glycemia \((P = 0.01, 15.7 \pm 1.2 \text{ vs } 7.7 \pm 0.4 \text{ mU/L})\), levels of total testosterone \((P < 0.0001, 2.9 \pm 0.2 \text{ vs } 1.0 \pm 0.1 \text{ nmol/L})\) and of plasma triglycerides (TG) \((P = 0.0001, 1.7 \pm 0.1 \text{ vs } 1.0 \pm 0.1)\). Prolactin levels in plasma were lower in women with PCOS compared with controls \((P = 0.0001, 73.1 \pm 11.7 \text{ vs } 148.8 \pm 9.4)\) (Table 2).

Genotype data
All SNPs were in Hardy-Weinberg equilibrium. Allele frequencies of SNPs in PCOS and controls were respectively 0.56 and 0.56 for rs699947, 0.51 and 0.54 for rs833061, 0.34 and 0.31 for rs1570360, 0.37 and 0.36 for rs833068, 0.25 and 0.22 for rs3025020 and 0.87 and 0.91 for rs3025039 (Table 3).

The study of LD pattern (assessed by \( D' \) index) in the region delimited by these SNPs showed relative high LD between SNPs rs699947, rs833061, rs1570360 and rs833068 (Fig. 1) allowing then reconstruction of haplotypes with these 4 polymorphisms. We observed 10 haplotypes among which 4 haplotypes were the most frequent: H1 (ACGG)(13.4 %), H2 (ACAG) (29.3 %), H7 (CTGG) (19.6 %) and H8 (CTGA) (32.3 %) (Table 4).

Reconstruction of the cladogram in the population allowed observing that H2 arose from H1 after the mutation of the SNP r1570360 while H7 appeared after the mutation of rs1570360, rs833061 and rs699947. Finally, H8 arose after the mutation of rs1570360, rs833061, rs699947 and rs833068 (Fig. 2).

Logistic regression showed the association of the genotype CT of rs3025039 with PCOS phenotype \((P = 0.03; \text{OR } 95 \% \text{ CI } = 2.05 [1.07 - 3.90])\) (Table 5) while non-

| Table 1 SNPs probe sequence | SNP | Assay ID | Probe sequence |
|-----------------------------|-----|----------|----------------|
| rs699947                    | C_8311602_10 | GCCACGCTAGTGGCCAGACCCTGGGGA[A/C]GATCTGGGTGGATAATCAGACTGAC |
| rs833061                    | C_1647381_10 | GAGTGTGTGCGTGTGGGGTTGAGGG[C/T]GTTGGAGCGGGGAGAAGGCCAGGGG |
| rs1570360                   | C_1647379_10 | AGCCCGGGCCCGAGCCGCTGGGA[A/G]GGGCTGAGGCTCGCCTGCCCTGACC |
| rs833068                    | C_11400864_10 | GACATGTCCCATTTGTGGGAACTGT[A/G]ACCCTTCCTGTGTGAGCTGGAGGCA |
| rs3025020                   | C_1647366_10 | GCTTCTGAGGAGGAGCCCTTATTC[A/G]GCCAAACCACATGACGCCACCCAGAG |
| rs3025039                   | C_16198794_10 | GCATTCCCGGGCGGGTGACCCAGCA[C/T]GGTCCCTCTTGGAATTGGATTCGCC |

| Table 2 Phenotypic features of our women cohort used in the study | PCOS women \((n = 118)\) | Controls \((n = 150)\) | \(P (\chi^2)\) |
|---------------------------------------------------------------|------------------|------------------|----------------|
| Age (years)                                                   | 29.8 ± 0.4       | 33.5 ± 0.5       | <0.0001        |
| BMI (kg/m\(^2\))                                             | 28.4 ± 0.7       | 23.1 ± 0.2       | <0.0001        |
| Random glycemia (mmol/L)                                     | 7.9 ± 0.2        | 4.5 ± 0.1        | <0.0001        |
| Fasting insulin (mU/L)                                       | 15.7 ± 1.2       | 7.7 ± 0.4        | 0.01           |
| Testosterone (nmol/L)                                        | 2.9 ± 0.2        | 1.0 ± 0.1        | <0.0001        |
| Prolactin (mU/L)                                             | 73.1 ± 11.7      | 148.8 ± 9.4      | 0.0001         |
| Triglycerides (mmol/L)                                       | 1.7 ± 0.1        | 1.0 ± 0.1        | 0.0001         |
| LDL cholesterol                                              | 3.1 ± 0.1        | 1.9 ± 0.2        | <0.0001        |
| MetS ATPIII (%)                                               | 34.7             | 0.0              | <0.0001        |

| Table 3 Allele frequencies of SNPs in PCOS and controls |
|--------------------------------------------------------|
| SNP          | Position | Minor Allele | Allele frequencies | \(P^*\) |
|--------------|----------|--------------|--------------------|--------|
| rs699947     | 43736389 | A            | 0.56               | 0.56   | 0.873 |
| rs833061     | 43737486 | C            | 0.51               | 0.54   | 0.656 |
| rs1570360    | 43737830 | A            | 0.34               | 0.31   | 0.520 |
| rs833068     | 43742527 | A            | 0.37               | 0.36   | 0.820 |
| rs3025020    | 43749110 | T            | 0.25               | 0.22   | 0.403 |
| rs3025039    | 43752536 | C            | 0.87               | 0.91   | 0.126 |

*Pearson’s chi square test
Parametric tests allowed observing a trend for correlation of the pair of haplotypes H2/H2 to prolactin levels in plasma ($P = 0.077; 193.5 \pm 94.3$ vs $45.7 \pm 7.2$). According to the calculation, this study had a power of 58.38%. PCOS is a disease that affects women at reproductive age and characterized by endocrine disorders as menses disturbance and subfertility and by metabolic abnormalities as insulin resistance, and glucose intolerance [14, 15]. Angiogenesis process has also been reported as probably implied in disorders of anovulation, subfertility and other pathogenic conditions as endometriosis. Since VEGF system plays a pivotal role in tissue vascularization, VEGFA gene is considered as candidate in reproductive abnormalities

**Table 4** List of haplotypes resulting from the combination of SNPs rs699947, rs833061, rs1570360 and rs833068 in the Tunisian population

| Haplotype | rs699947 (A/C) | rs833061 (C/T) | rs1570360 (G/A) | rs833068 (G/A) | Prevalence (%) | $P$ ($\chi^2$) |
|-----------|----------------|----------------|-----------------|----------------|----------------|--------------|
| H1        | A              | C              | G               | G              | 13.4           | 0.749        |
| H2        | A              | C              | A               | G              | 29.3           | 0.595        |
| H3        | A              | C              | A               | A              | 0.9            | 0.021        |
| H4        | A              | T              | A               | G              | 0.4            | 0.081        |
| H5        | C              | C              | G               | G              | 0.2            | 0.059        |
| H6        | C              | C              | G               | A              | 2.1            | 0.781        |
| H7        | C              | T              | G               | G              | 19.6           | 0.725        |
| H8        | C              | T              | G               | A              | 32.3           | 0.389        |
| H9        | C              | T              | A               | A              | 0.4            | 0.068        |
| H10       | C              | T              | A               | A              | 1.5            | 0.088        |

H1 is the ancestral haplotype (haplotype of chimpanzee: Pan troglodytes)

$P$ ($\chi^2$) indicates the significance of variability of each polymorphism between the two groups.

NS not statistically significant
as PCOS. Many studies have been carried-out and concluded in a part of them that VEGFA levels in serum or follicular fluid are higher in women with PCOS [16–19]. In another hand, previous studies in Korean and Turkish populations reported the association of VEGFA gene with PCOS through many SNPs and one haplotype [6–8]. In that context, our investigation focused on the study of VEGFA gene association with PCOS in a Tunisian population well characterized at the phenotypic level, through 6 SNPs and their combination into haplotypes in the population. We observed the association of the gene (SNP rs3025039) with PCOS phenotype and a trend of correlation (pair of haplotypes H2/H2) with prolactin levels in plasma. Prolactin is secreted mainly by the pituitary gland and is implied in many processes as lactation and also tissue vascularization [20]. Indeed, many studies showed the role of prolactin as a pro-angiogenic factor while its enzymatically cleaved 16 kDa N-terminal fragment has a well-defined anti-angiogenic effect [21]. Moreover, it was shown the effect of prolactin on the induction of VEGF expression [22–24]. To the best of our knowledge, our study is the first work that reports the correlation, even with a trend, of VEGFA gene variations with prolactin plasma levels. These findings suggest possible regulation and/or feedback control of prolactin secretion pathway through VEGF and the role of VEGFA gene variation in this process. Deeper genetic investigations taking into account more SNPs and larger locus are necessary to demystify these molecular pathways.

Differences of VEGF plasma levels between PCOS and healthy women were observed in some populations but not in others and this could be due to genetic differences between ethnic groups [16–19] Studying VEGFA gene association in complex disorders should take into account the gene variability in the population through the LD pattern assessment and SNPs combination into haplotypes. We reported in a previous study the role of haplotypes as powerful genetic markers for better characterization of gene association in the Tunisian population and observed Fat mass and obesity associated (FTO) gene association with PCOS through haplotypes but not through SNPs taken alone [12]. Indeed, we

| Table 5 Distribution of VEGF genotype in PCOS cases and control women |
|---|
| 1/1" | 1/2" | 2/2" |
| PCOS | Controls | PCOS | Controls | PCOS | Controls | P |
| rs699947 | 0.3 | 0.3 | 0.53 | 0.51 | 0.17 | 0.19 | 0.65 |
| rs833061 | 0.28 | 0.28 | 0.46 | 0.51 | 0.25 | 0.21 | 0.38 |
| rs1570360 | 0.48 | 0.5 | 0.36 | 0.38 | 0.16 | 0.12 | 0.71 |
| rs833068 | 0.36 | 0.43 | 0.53 | 0.42 | 0.11 | 0.15 | 0.09 |
| rs3025020 | 0.58 | 0.6 | 0.34 | 0.35 | 0.08 | 0.05 | 0.38 |
| rs3025039 | 0.75 | 0.85 | 0.23 | 0.13 | 0.02 | 0.03 | 0.03 |

*Genotypes were coded as per "1" = major allele, "2" = minor allele

\(^b\)Frequency

Fig. 3 Comparison of linkage disequilibrium (LD) pattern (LD is assessed by \(r^2\) index) in the VEGF locus delimited between SNPs rs699947 and rs3025039, between the studied women population and the CEU reference population. Numbers in the squares indicates levels of LD as informed by \(r^2\) index.
observed LD pattern in the FTO locus less in the Tunisian population compared with the CEU Caucasian one justifying so the ability of haplotypes for detecting genetic association in such conditions. In the present study, the investigation of the LD pattern in VEGF locus showed a similar LD pattern between the Tunisian population and the CEU one (Fig. 3). However, we found more haplotypes in the Tunisian population than in CEU (22 haplotypes vs 16 haplotypes) suggesting more recombination rate operated in Tunisians. Although we were not able to observe any advantage of using haplotypes compared with SNPs taken alone in this study, these results could suggest a more complex anthropogenetics context concerning VEGF locus or the need for a better characterization of this locus by using more density of SNPs at larger genomic region/scale and using larger cohorts of patients. Therefore, better management approaches can be identified [25]. Additionally, despite the relatively reduced size of our cohort, it remains that the powering of the study was acceptable (58.38 %) attesting then for the reliability of our findings.

Conclusions
Deeper investigations of VEGFA gene encompassing larger regions in the locus and using more SNPs need to be envisioned in order to better characterize the gene association in the Tunisian population and to shed light on the genetic/genomic players involved and develop better diagnostic, management and therapeutic approaches.

Acknowledgments
This work was supported by the recurrent budget from Laboratory of Human genome and multifactorial diseases (LR12ES07) at University of Monastir Tunisia.

Declaration
This article has been published as part of BMC Genomics Volume 17 Supplement 9, 2016: Proceedings of the 3rd International Genomic Medicine Conference: genomics. The full contents of the supplement are available online at http://bmcgenomics.biomedcentral.com/articles/supplements/volume-17-supplement-9.

Availability of data and material
The data sets supporting the results are included within the article.

Authors’ contribution
TM initiated and designed the study, and is responsible for the facility in which the study was conducted. AB wrote the first draft of the manuscript and was responsible for the genetic analysis, the statistical analysis and interpretation of the data. MA, OK, FHB contributed to the original data collection. FM, MS, SH, FJ contributed to the biological and immunoassay. MAE, MA, MHAQ have read the manuscript, revised it, agreed that the work is ready for publication.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
All patients gave written consent for participating and in the study and for publication including consequences that may result.

Ethics approval and consent to participate
The study was approved by the Medical Ethics and Research Committee of the University Hospital Farhat Hached (Sousse).

Publication fees declaration
The publication charges of this manuscript was paid by the Centre of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia.

Author details
1Laboratory of Human Genome and multifactorial diseases, LR12ES07, Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia.
2Department of Gynecoc Obstetric, University Hospital F. Hached, Sousse, Tunisia.
3University Hospital F. Hached, Unit of Reproductive Medicine, Sousse, Tunisia.
4Center of Excellence in Genomic Medicine Research (CEGMR), King Abdulaziz University, Jeddah, Saudi Arabia.

Published: 17 October 2016

References
1. Elmann DA. Polycystic Ovary Syndrome. N Engl J Med. 2005;352(12):1223–36.
2. Klein J, Craven M, Vuyugin PM. Polycystic Ovarian Syndrome. Adolesc Med State Rev. 2015;26(2):326–42.
3. Pan H-A, Wu M-H, Cheng Y-C, Li C-H, Chang F-M. Quantification of Doppler signal in polycystic ovary syndrome using three-dimensional power Doppler ultrasonography: a possible new marker for diagnosis. Human Reproduction. 2002;17(1):201–6.
4. Geva E, Jaffe RB. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril. 2000;74(3):429–38.
5. Shibuya M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer. 2011;2(12):1079–105.
6. Lee EJ, Oh B, Lee JY, Kimm K, Park JM, Baek IH. Association study between single nucleotide polymorphisms in the VEGF gene and polycystic ovary syndrome. Fertil Steril. 2008;89(6):1751–9.
7. Vural P, Kusku-Kiraz Z, Dogru-Abbasoglu S, Cil E, Karadag B, Akgul C, Uysal M. Vascular endothelial growth factor −2578 A/C, −460 T/C and +405 G/C polymorphisms in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2009;147(1):57–60.
8. Gunuvaih P, Govatati S, Reddy TV, Lomada D, Deenadayal M, Shivaji S, Bhanoori M. The VEGF +405 G > C 5′ untranslated region polymorphism and risk of PCOS; a study in the South Indian Women. J Ass Reprod Genet. 2014;31(10):1383–9.
9. Vural P, Kusku-Kiraz Z, Dogru-Abbasoglu S, Cil E, Karadag B, Uysal M. Vascular endothelial growth factor +405GC/C, −460 T/C and −2578 A/C polymorphisms are not associated with insulin resistance in polycystic ovary syndrome. Int J Immunogenet. 2010;37(4):259–43.
10. Choudhuri S, Chowdhury IH, Das S, Dutta D, Saha A, Sarkar R, Mandal UK, Mukherjee S, Bhattacharya B. Role of NF-kappaB activation and VEGF gene polymorphisms in VEGF up regulation in non-proliferative and proliferative diabetic retinopathy. Mol Cell Biochem. 2015;405(1–2):265–79.
11. Ben Salem A, Attaoua R, Mitraou N, Belkahla S, Ezzidi I, Ajina M, Souissi M, Pouchelet P, Vintila M, Gigoreescu F, et al. Common polymorphisms of calpain-10 and the risk of polycystic ovary syndrome in Tunisian population: a case–control study. Mol Biol Rep. 2014;41(10):6569–74.
12. Ben Salem A, Attaoua R, Mitraou N, Meddeb S, Kacem O, Ajina M, Souissi M, Pouchelet P, Normand C, Mahjoub T, et al. Haplotyping strategy highlights the specificity of FTO gene association with polycystic ovary syndrome in Tunisian women population. Gene. 2015;565(2):166–70.
13. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility. 2004;81(1):19–25.
14. Palloua E, Diamanti-Kandarakis E. Polycystic ovary syndrome (PCOS) and endocrine disrupting chemicals (EDCs). Rev Endocr Metab Disord. 2015;16(4):365–71.
15. Davies N. PCOS: Polycystic Ovarian Syndrome. Diabetes Self Manag. 2016;33(1):144–7.
16. Agrawal R, Jacobs H, Payne N, Conway G. Concentration of vascular endothelial growth factor released by cultured human luteinized granulosa cells is higher in women with polycystic ovaries than in women with normal ovaries. Fertil Steril. 2002;78(6):164–9.
17. Abd El Aal DE, Mohamed SA, Amine AF, Meki AR. Vascular endothelial growth factor and insulin-like growth factor-1 in polycystic ovary syndrome and their relation to ovarian blood flow. Eur J Obstet Gynecol Reprod Biol. 2005;118(2):219–24.

18. Artini PG, Monti M, Matteucci C, Valentino V, Cristello F, Genazzani AR. Vascular endothelial growth factor and basic fibroblast growth factor in polycystic ovary syndrome during controlled ovarian hyperstimulation. Gynecol Endocrinol. 2006;22(8):465–70.

19. Artini PG, Ruggiero M, Parisen Toldin MR, Monteleone P, Monti M, Cela V, Genazzani AR. Vascular endothelial growth factor and its soluble receptor in patients with polycystic ovary syndrome undergoing IVF. Hum Fertil (Camb). 2009;12(1):40–4.

20. VanKlompenberg MK, Manjarin R, Donovan CE, Trott JF, Hovey RC. Regulation and localization of vascular endothelial growth factor within the mammary glands during the transition from late gestation to lactation. Domest Anim Endocrinol. 2016;54:37–47.

21. Corbacho AM, Martínez de la Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol. 2002;173:219–38.

22. Goldhar AS, Vonderhaar BK, Trott JF, Hovey RC. Prolactin-induced expression of vascular endothelial growth factor via Egfr-1. Mol Cell Endocrinol. 2005;232(1–2):9–19.

23. Malaguarnera L, Imbesi RM, Scuto A, D’Amico F, Licata F, Messina A, Sanfilippo S. Prolactin increases HO-1 expression and induces VEGF production in human macrophages. J Cell Biochem. 2004;91(1):197–206.

24. Nakajima K-I, Nakamura M, Ishisaki A, Koizaki T. Synergistic Effect of Dexamethasone and Prolactin on VEGF Expression in Bovine Mammary Epithelial Cells via p44/p42 MAP Kinase. Asian-Aust J Anim Sci. 2009;22(6):788–95.

25. Seow KM, Lee WL, Wang PH. A challenge in the management of women with polycystic ovary syndrome. Taiwan J Obstet Gynecol. 2016;55(2):157–8.